Cooper, Arthur J.L.

Publications

Sort by

Co-Author Network

selected publications

Cystamine and cysteamine as inhibitors of transglutaminase activity in vivo. Bioscience reports. 2018 Review GET IT
Times cited: 28
The Enzymology of 2-Hydroxyglutarate, 2-Hydroxyglutaramate and 2-Hydroxysuccinamate and Their Relationship to Oncometabolites. Biology. 2017 Academic Article GET IT
Times cited: 40
Fluorination at the 4 position alters the substrate behavior of L-glutamine and L-glutamate: Implications for positron emission tomography of neoplasias. Journal of fluorine chemistry. 2016 Academic Article GET IT
Times cited: 4
Central Role of Glutamate Metabolism in the Maintenance of Nitrogen Homeostasis in Normal and Hyperammonemic Brain. Biomolecules. 2016 Review GET IT
Times cited: 124
Simultaneous determination of tricarboxylic acid cycle metabolites by high-performance liquid chromatography with ultraviolet detection. Analytical biochemistry. 2016 Academic Article GET IT
Times cited: 14
Erratum to: ω-Amidase: an underappreciated, but important enzyme in L-glutamine and L-asparagine metabolism; relevance to sulfur and nitrogen metabolism, tumor biology and hyperammonemic diseases. Amino acids. 2015 Article GET IT
Times cited: 1
HPLC determination of α-ketoglutaramate [5-amino-2,5-dioxopentanoate] in biological samples. Analytical biochemistry. 2015 Academic Article GET IT
Times cited: 6
ω-Amidase: an underappreciated, but important enzyme in L-glutamine and L-asparagine metabolism; relevance to sulfur and nitrogen metabolism, tumor biology and hyperammonemic diseases. Amino acids. 2015 Review GET IT
Times cited: 38
Critical Evaluation of the Changes in Glutamine Synthetase Activity in Models of Cerebral Stroke. Neurochemical research. 2015 Review GET IT
Times cited: 26
Inhibition of human glutamine synthetase by L-methionine-S,R-sulfoximine-relevance to the treatment of neurological diseases. Metabolic brain disease. 2013 Academic Article GET IT
Times cited: 25
γ-Glutamylamines and neurodegenerative diseases. Amino acids. 2012 Review GET IT
Times cited: 17
Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington disease. EMBO molecular medicine. 2010 Academic Article GET IT
Times cited: 113
Transglutaminase activation in neurodegenerative diseases. Future neurology. 2009 Academic Article GET IT
Times cited: 34
Measurement of sulfur-containing compounds involved in the metabolism and transport of cysteamine and cystamine. Regional differences in cerebral metabolism. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2009 Academic Article GET IT
Times cited: 32
Transglutaminases and neurodegeneration. Journal of neurochemistry. 2009 Review GET IT
Times cited: 77
A nonradioactive dot blot assay for transglutaminase activity. Analytical biochemistry. 2009 Academic Article GET IT
Times cited: 8
Increased levels of gamma-glutamylamines in Huntington disease CSF. Journal of neurochemistry. 2008 Academic Article GET IT
Times cited: 49
Enzyme-catalyzed side reactions with molecular oxygen may contribute to cell signaling and neurodegenerative diseases. Neurochemical research. 2007 Review GET IT
Times cited: 41
Cisplatin-induced toxicity is associated with platinum deposition in mouse kidney mitochondria in vivo and with selective inactivation of the alpha-ketoglutarate dehydrogenase complex in LLC-PK1 cells. Biochemistry. 2006 Academic Article GET IT
Times cited: 41
Redox-sensitive proteins are potential targets of garlic-derived mercaptocysteine derivatives. The Journal of nutrition. 2006 Review GET IT
Times cited: 70
Inhibitors of the alpha-ketoglutarate dehydrogenase complex alter [1-13C]glucose and [U-13C]glutamate metabolism in cerebellar granule neurons. Journal of neuroscience research. 2006 Academic Article GET IT
Times cited: 48
Cysteine S-conjugate beta-lyases. Amino acids. 2006 Review GET IT
Times cited: 75
Mitochondrial aconitase is a transglutaminase 2 substrate: transglutamination is a probable mechanism contributing to high-molecular-weight aggregates of aconitase and loss of aconitase activity in Huntington disease brain. Neurochemical research. 2005 Academic Article GET IT
Times cited: 44
Phosphonate analogues of alpha-ketoglutarate inhibit the activity of the alpha-ketoglutarate dehydrogenase complex isolated from brain and in cultured cells. Biochemistry. 2005 Academic Article GET IT
Times cited: 68
Comparative kinetic analysis reveals that inducer-specific ion release precedes the mitochondrial permeability transition. Biochimica et biophysica acta. 2005 Academic Article GET IT
Times cited: 31
Metabolism of [13N]ammonia in rat lung. Neurochemistry international. 2005 Academic Article GET IT
Times cited: 21
Treatment of YAC128 mice and their wild-type littermates with cystamine does not lead to its accumulation in plasma or brain: implications for the treatment of Huntington disease. Journal of neurochemistry. 2005 Academic Article GET IT
Times cited: 52
Transglutaminase activity is present in highly purified nonsynaptosomal mouse brain and liver mitochondria. Biochemistry. 2005 Academic Article GET IT
Times cited: 48
Mechanism for the inhibition of transglutaminase 2 by cystamine. Biochemical pharmacology. 2005 Academic Article GET IT
Times cited: 92
Aminotransferase, L-amino acid oxidase and beta-lyase reactions involving L-cysteine S-conjugates found in allium extracts. Relevance to biological activity?. Biochemical pharmacology. 2005 Academic Article GET IT
Times cited: 53
The role of glutamine transaminase K (GTK) in sulfur and alpha-keto acid metabolism in the brain, and in the possible bioactivation of neurotoxicants. Neurochemistry international. 2004 Review GET IT
Times cited: 97
Transglutaminases - possible drug targets in human diseases. Current drug targets. CNS and neurological disorders. 2004 Review GET IT
Times cited: 39
L-alanine-glyoxylate aminotransferase II of rat kidney and liver mitochondria possesses cysteine S-conjugate beta-lyase activity: a contributing factor to the nephrotoxicity/hepatotoxicity of halogenated alkenes?. The Biochemical journal. 2003 Academic Article GET IT
Times cited: 20
Therapeutic effects of cystamine in a murine model of Huntington's disease. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2002 Academic Article GET IT
Times cited: 296
Cross linking of polyglutamine domains catalyzed by tissue transglutaminase is greatly favored with pathological-length repeats: does transglutaminase activity play a role in (CAG)(n)/Q(n)-expansion diseases?. Neurochemistry international. 2002 Review GET IT
Times cited: 66
The role of transglutaminases in neurodegenerative diseases: overview. Neurochemistry international. 2002 Editorial Article GET IT
Times cited: 22
N(epsilon)-(gamma-L-glutamyl)-L-lysine (GGEL) is increased in cerebrospinal fluid of patients with Huntington's disease. Journal of neurochemistry. 2001 Academic Article GET IT
Times cited: 82
A sensitive fluorometric assay for tissue transglutaminase. Analytical biochemistry. 2001 Academic Article GET IT
Times cited: 28

more ...

less ...

Background

education and training

D.Sc., London University (United Kingdom) 1986
Ph.D., Cornell University 1974
M.Sc., Imperial College of Science and Technology (United Kingdom) 1969
B.Sc., Northern Polytechnic, London University (United Kingdom) 1967

Contact

full name

Arthur J.L. Cooper

VIVO Weill Cornell Medical College

Arthur J.L. Cooper Adjunct Professor of Biochemistry in Neuroscience

Publications

selected publications

Background

education and training

Contact

full name